Compass Therapeutics, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 3/100
What the filing says
CEO Thomas Schuetz and CFO Barry Shin certified the Q2 2026 10-Q (period ended June 30, 2026, filed August 6, 2026) per Sarbanes-Oxley requirements. Standard certifications attest to report accuracy, internal control effectiveness, and absence of material misstatements or fraud. No operational, financial, or strategic changes disclosed in these exhibits.
Why this rating
Boilerplate SOX compliance certification exhibits. No substantive business, financial, or strategic content; routine periodic disclosure requirement.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.